Nuwellis, Inc. - What You Need to Know

Thinking about investing in Nuwellis? Before you put your hard-earned money down, let’s break down what this company is doing.

Note: Nuwellis is a publicly traded company (NASDAQ: NUWE). They are currently raising money through a "follow-on" stock offering.

1. What does this company actually do?

Nuwellis manages fluid for patients suffering from fluid overload, often caused by heart or kidney failure. Their main product, the Aquadex SmartFlow system, is a medical device that performs ultrafiltration therapy. It acts like a "kidney outside the body," gently removing excess fluid from a patient’s blood when standard medications fail. The company makes money by selling these consoles and the single-use blood sets required for each treatment.

2. What is happening with this new offering?

As of mid-2026, Nuwellis is raising cash by selling common stock and pre-funded warrants.

• The Package: Investors get shares bundled with "Series C" and "Series D" warrants. A warrant is a contract giving you the right to buy more shares at a set price later.
• The "Zero Cash" Option: The Series D warrants allow holders to get shares without paying extra cash under certain conditions. Because of this, the company won't receive more money from these specific warrants, which limits future cash flow from this source.
• The "Best Efforts" Reality: An underwriter is selling these shares on a "best efforts" basis. This means the investment firm isn't required to sell a specific number of shares. If demand is low, the company will raise much less than its $4.4 million goal, which would immediately threaten their ability to keep operating.

3. Why are they doing this?

Nuwellis is in a "growth phase" that requires a lot of cash. They are spending heavily on sales and marketing to get hospitals to use the Aquadex system. The company plans to use the money from this offering to cover general operations through the end of 2026. If they don't hit their sales goals or find more funding, they will run out of cash. This would force them to raise more money, which means issuing more shares and reducing your ownership percentage.

4. What are the main risks?

Investing in Nuwellis involves high risk and volatility:

• The "Going Concern" Risk: The company’s auditors have expressed doubt about Nuwellis’s ability to stay in business. Without this offering and higher sales, the company may not have enough cash to pay its bills.
• Regulatory Hurdles: Nuwellis faces strict FDA oversight. If they fail to follow manufacturing rules or report device issues correctly, the FDA could issue warnings, fines, or recalls, which could stop sales of the Aquadex system entirely.
• Manufacturing Bottlenecks: Nuwellis relies on one manufacturer, KDI Precision Manufacturing, for all consoles and supplies. They have no backup supplier. If KDI has labor issues or supply chain failures, Nuwellis cannot fulfill hospital orders.
• Dilution: Issuing millions of new shares and warrants increases the total share count. This reduces your ownership percentage and can push the stock price down.
• Healthcare Reform: The business depends on healthcare policy. If Medicare or Medicaid changes how they pay for ultrafiltration, hospitals might choose cheaper, traditional treatments instead of the Aquadex.

5. The Bottom Line

Nuwellis is a high-risk, speculative investment. They have specialized technology but face serious financial and operational hurdles. They have limited cash, rely on one manufacturer, and face intense government oversight. You are betting that their device will become popular in hospitals before they run out of money or hit a regulatory wall.

Before you decide:

• Read the Prospectus: Because of the complex warrant structures and the company's shaky finances, please read the full "Prospectus" on the SEC website. It contains the fine print that could impact your investment.
• Check the Cash Runway: Keep an eye on their quarterly earnings reports to see if they are actually hitting their sales targets or if they are burning through cash faster than expected.

Disclaimer: I am an AI, not a financial advisor. This is a volatile investment. Please consult with a professional before making any financial decisions.